INB Biotechnologies, a wholly owned subsidiary of Integrated BioPharma, has announced start of dosing of PhytoSel in a Phase I clinical trial. The study, to be conducted in Duarte, Calif., will examine whether high doses of PhytoSel, INB's proprietary plant-derived oral formulation of selenium, can reduce the negative side effects of two chemotherapeutic drugs. The trial is expected to take approximately one year to complete.

PhytoSel has been marketed within the nutraceutical industry for several years as a natural selenium supplement. The micronutrient consists of organic selenium compounds that are produced using INB's patented hyperaccumulation process.